natgillin/translations-raw huggingface dataset:
Sildenafil er kontraindiceret ved samtidig administration af VIRACEPT (se kontraindikationer)
Sildenafil is contraindicated when coadministered with VIRACEPT (see contraindications).
Sildenafil Kontraindiceret, når det anvendes til behandling af pulmonal hypertension (PAH).
Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only.
Sildenafil må ikke anvendes til patienter med pulmonal hypertension sekundært til seglcelleanæmi.
Sildenafil should not be used in patients with pulmonary hypertension secondary to sickle cell anaemia.
Sildenafil ratiopharm 100 mg filmovertrukne tabletter Sildenafil
Sildenafil ratiopharm 100 mg film-coated tablets Sildenafil
Sildenafil ratiopharm 25 mg filmovertrukne tabletter Sildenafil
Sildenafil ratiopharm 25 mg film-coated tablets Sildenafil
Sildenafil ratiopharm 25 mg filmovertrukne tabletter.
NAME OF THE MEDICINAL PRODUCT
Sildenafil ratiopharm 50 mg filmovertrukne tabletter Sildenafil
Sildenafil ratiopharm 50 mg film-coated tablets Sildenafil
Sildenafil ratiopharm er et "generisk lægemiddel".
Sildenafil ratiopharm is a ‘generic medicine’.
Sildenafil ratiopharm er hvide til off-white, aflange filmovertrukne tabletter med kant og delekærv på den ene side.
Sildenafil ratiopharm are white to off-white, oblong film-coated tablets with edge and score line on one side.
Sildenafil ratiopharm er hvide til off-white, aflange filmovertrukne tabletter med kant.
Sildenafil ratiopharm are white to off-white, oblong film-coated tablets with edge.
Sildenafil ratiopharm er ikke indiceret til anvendelse til kvinder.
Sildenafil ratiopharm is not indicated for use by women.
Sildenafil ratiopharm er ikke indiceret til personer under 18 år.
Sildenafil ratiopharm is not indicated for individuals below 18 years of age.
Sildenafil ratiopharm indeholder det aktive stof sildenafil, der tilhører en gruppe medicin, som kaldes fosfodiesterase type 5 (PDE5)-hæmmere -hæmmere.
Sildenafil ratiopharm contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Sildenafil Teva 100 mg filmovertrukne tabletter EU/1/09/584/014
Sildenafil Teva 100 mg film-coated tablets
Sildenafil Teva er et "generisk lægemiddel".
Sildenafil Teva is a ‘generic medicine’.
Sildenafil Teva er ikke beregnet til at bruges af kvinder.
Sildenafil Teva is not indicated for use by women.
Sildenafil Teva er ikke beregnet til personer under 18 år.
Sildenafil Teva is not indicated for individuals below 18 years of age.
Sildenafil Teva er ikke indiceret til anvendelse til kvinder.
Sildenafil Teva is not indicated for use by women.
Sildenafil Teva hjælper kun til erektion ved seksuel stimulation.
Sildenafil Teva will only help you to get an erection if you are sexually stimulated.
Sildenafil Teva indeholder det aktive stof sildenafil, der tilhører en gruppe medicin, som kaldes fosfodiesterase type 5 (PDE5)-hæmmere.
Sildenafil Teva contains the active substance sildenafil which belongs to a group of medicines called phosphodiesterase type 5(PDE5) inhibitors.
sildenafil til behandling af pulmonal
ildenafil for the treatment of
sildenafil til behandling af pulmonal
recommended when
sildenafil – til behandling af impotens (erektil dysfunktion)
ildenafil – to treat erectile dysfunction
Sildenafil,
Sildenafil
Sildenafil, bør anvendes med forsigtighed hos patienter med anatomisk deformitet af penis (som f.eks. vinkling, kavernøs fibrose eller Peyronies sygdom), eller hos patienter med lidelser, som kan prædisponere til priapisme (som f.eks. seglcelleanæmi, multipelt myelom eller leukæmi).
Sildenafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).
Sildenafil, Kun kontraindiceret ved brug til behandling af pulmonal arteriel hypertension (PAH).
Sildenafil Contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) only.
sildenafil, som er et lægemiddel, der bruges til at behandle rejsningsproblemer eller for højt blodtryk i lungerne. lægemidler, som øger mængden af kalium i blodet.
ildenafil, a medicine used to treat erectile dysfunction or lung hypertension. medicines that increase the amount of potassium in the blood.
Sildenafil, tadalafil og vardenafil
Sildenafil, tadalafil, and
Sildenafil, tadalafil og vardenafil
Sildenafil, tadalafil, and vardenafil are
sildenafil, tadalafil, lægemidler, der anvendes til at behandle impotens og pulmonal hypertension, en lungesygdom, der gør det vanskeligt at trække vejret
ildenafil, tadalafil, medicines used to treat impotence and pulmonary hypertension, a lung disease that makes breathing difficult
Sildenafil-dosis bør ikke overstige max.
Sildenafil dose should not exceed a maximum of
Sildenafil/ Tenofovirdisoproxilfumarat
Sildenafil/Tenofovir disoproxil fumarate
Sildenafil/Emtricitabin
Sildenafil/Emtricitabine
Sildenafil: Samtidig administration af bosentan 125 mg to gange dagligt (steady-state) og sildenafil 80 mg tre gange dagligt (ved steady-state) i 6 dage til raske forsøgspersoner resulterede i en reduktion i sildenafils AUC på 63% og en stigning i bosentans AUC på 50%.
Sildenafil: co-administration of bosentan 125 mg twice daily (steady state) with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63% decrease in the sildenafil AUC and a 50% increase in the bosentan AUC.
Sildenafil: Ved steady-state var eksponeringen for sildenafil 20 mg t.i.d øget med 15 % ved samtidig administration af macitentan 10 mg én gang dagligt.
Sildenafil: At steady-state, the exposure to sildenafil 20 mg t.i.d. was increased by 15% during concomitant administration of macitentan 10 mg once daily.
Sildenafils totale clearance er 41 l/time med en deraf følgende halveringstid på 3-5 timer.
The total body clearance of sildenafil is 41 l/h with a resultant terminal phase half-life of 3-5 h.
Sildenafils totale kropsclearance er 41 l/t med en deraf følgende halveringstid på 3-5 timer.
The total body clearance of sildenafil is 41 L/h with a resultant terminal phase half-life of 3-5 h.
Sildenalfil Actavis er ikke indiceret til personer under 18 år.
Sildenafil Actavis is not indicated for individuals below 18 years of age.
Sileo 0,1 mg/ml mundhulegel
Sileo 0.1 mg/ml oromucosal gel
Sileo 0,1 mg/ml mundhulegel til hunde
Sileo 0.1 mg/ml oromucosal gel for dogs
Sileo 0,1 mg/ml mundhulegel til hunde dexmedetomidin hydrochlorid
Sileo 0.1 mg/ml oromucosal gel for dogs dexmedetomidine hydrochloride
Sileo blev givet til 89 hunde, og 93 hunde fik en uvirksom behandling.
Sileo was given to 89 dogs and 93 dogs received a dummy treatment.
Sileo er en gennemsigtig, grøn mundhulegel, der indeholder 0,1 mg/ml dexmedetomidin hydrochlorid (det aktive stof), svarende til 0,09 mg/ml dexmedetomidin.
Sileo is a translucent, green oromucosal gel containing 0.1 mg/ml dexmedetomidine hydrochloride (active substance), equivalent to 0.09 mg/ml dexmedetomidine.
Sileo påføres på slimhinderne i hundens mundhule mellem kinden og gummerne fra den fyldte mundsprøjte.
Sileo is applied to the lining of the dog’s mouth between the cheek and gum from the pre-filled oral syringe.
Sileo påføres slimhinderne i hundens mundhule mellem kinden og gummerne.
Sileo is administered onto the oral mucosa between the dog’s cheek and gum.
Sileo-gel i doser, der ligger over det anbefalede, kan også fremkalde en række øvrige alpha-2 adrenoceptor-formidlede virkninger, herunder pupiludvidelse, hæmning af mave-tarm- kanalens motoriske og sekretoriske funktioner, midlertidige AV-blokeringer, diurese og hyperglykæmi.
Higher than recommended doses of Sileo gel may also induce a number of other alpha-2 adrenoceptor mediated effects, which include mydriasis, depression of motor and secretory functions of the gastrointestinal tract, temporary AV-blocks, diuresis and hyperglycaemia.
Silgard bør anvendes i overensstemmelse med officielle anbefalinger.
The use of Silgard should be in accordance with official recommendations.
Silgard bør gives efter et program med 3 doser:
Silgard should be administered according to a 3-dose schedule:
Silgard bør indgives efter et program med 3 doser (0,5 ml ved måned 0, 2 og 6).
Silgard should be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule.
Silgard er beregnet til unge og voksne fra 9–års alderen og ældre.
Silgard is intended for adolescents and adults from 9 years of age onwards.
Silgard er en vaccine til brug fra 9 års alderen til forebyggelse af: præmaligne, genitale læsioner (cervikale, vulvale og vaginale), præmaligne anale læsioner, cervixcancer og analcancer kausalt relateret til visse onkogene typer af human papillomavirus (HPV). kondylomer (condyloma acuminata) kausalt relateret til specifikke HPV-typer.
Silgard is a vaccine for use from the age of 9 years for the prevention of: premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types genital warts (condyloma acuminata) causally related to specific HPV types.
Silgard er udelukkende beregnet til profylaktisk anvendelse og har ingen effekt på aktive HPV- infektioner eller eksisterende klinisk sygdom.
Silgard is for prophylactic use only and has no effect on active HPV infections or established clinical disease.
Silgard fremkaldte høje anti-HPV geometriske middeltitre (GMT’er) én måned efter 3. dosis i alle testede aldersgrupper.
Silgard induced high anti-HPV Geometric Mean Titres (GMTs) 1 month Postdose 3 in all age groups tested.
Silgard human papillomavirusvaccine [type 6, 11, 16 og 18] (rekombinant, adsorberet)
Silgard human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Silgard indgives som en injektion gennem huden ind i musklen (helst en muskel i overarmen eller låret).
Silgard will be given as an injection through the skin into the muscle (preferably the muscle of the upper arm or thigh).
Silgard indgivet til hanrotter med fuld human dosis (120 mikrogram total protein) havde ingen indflydelse på reproduktionsevne, herunder fertilitet, spermtal eller spermmotilitet og der var ingen betydelige vaccine-relaterede eller histomorfologiske ændringer i testiklerne og ingen effekt på testikelvægten.
Silgard administered to male rats at the full human dose (120 mcg total protein) had no effects on reproductive performance including fertility, sperm count, and sperm motility, and there were no vaccine-related gross or histomorphologic changes on the testes and no effects on testes weights.
Silgard kan fremstå som en klar væske med et hvidt præcipitat (bundfald) før omrystning.
Silgard may appear as a clear liquid with a white precipitate prior to agitation.
Silgard kan gives samtidig med en Hepatitis B-vaccine eller med en kombineret boostervaccine indeholdende difteri (d) og tetanus (T) med enten pertussis (kighoste) [acellulær komponent] (aP) og/eller poliomyelitis [inaktiveret] (IPV) (TdaP, Td-IPV, TdaP-IPV vacciner) på et separat injektionssted (et andet sted på kroppen, f.eks. den anden arm eller det andet ben) under samme besøg.
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of your body, e.g. the other arm or leg) during the same visit.
Silgard kan gives som et program med 2 doser:
Silgard can be administered according to a 2-dose schedule:
Silgard leveres i en fyldt injektionssprøjte klar til brug til intramuskulær injektion (i.m.) fortrinsvis i deltoideaområdet på overarmen.
Silgard is available in a pre-filled syringe ready to use for intramuscular injection (IM), preferably in the deltoid area of the upper arm.
Silgard vil muligvis ikke have en optimal virkning hvis: den anvendes sammen med medicin, der hæmmer immunsystemet.
Silgard may not have an optimal effect if: used with medicines that suppress the immune system.
Silgard vil muligvis ikke have en optimal virkning hvis: det anvendes sammen med medicin, der hæmmer immunsystemet.
Silgard may not have an optimal effect if: used with medicines that suppress the immune system.
Silgard, injektionsvæske, suspension
Silgard, suspension for injection
Silgard, injektionsvæske, suspension i fyldt injektionssprøjte.
Silgard, suspension for injection in a pre-filled syringe.
Silgard, injektionsvæske, suspension i fyldt injektionssprøjte.
Silgard, suspension for injection in a pre-filled syringe:
Silgard, injektionsvæske, suspension i fyldt injektionssprøjte: EU/1/06/357/003
Silgard, suspension for injection in a pre-filled syringe:
Silgard, injektionsvæske, suspension i fyldt sprøjte
Silgard, suspension for injection in a pre-filled syringe
Silgard, injektionsvæske, suspension i fyldt sprøjte
Silgard, suspension for injection in a pre-filled syringe.
Silgard, injektionsvæske, suspension – hætteglas med én dosis, pakning med 1, 10, 20 stk.
Silgard, suspension for injection – single dose vial, pack of 1, 10, 20
Silgard, injektionsvæske, suspension.
Silgard, suspension for injection:
Silgard, injektionsvæske, suspension– fyldt sprøjte med én kanyle, pakning med 1, 10, 20
Silgard, suspension for injection – pre-filled syringe with 1 needle, pack of 1, 10, 20
Silgard, injektionsvæske, suspension– fyldt sprøjte uden kanyle, pakning med 1, 10, 20
Silgard, suspension for injection – pre-filled syringe without needle, pack of 1, 10, 20
Silgard, injektionsvæske.
SUMMARY OF PRODUCT CHARACTERISTICS
Silgard, injetionsvæske, suspension– fyldt sprøjte med to kanyler, pakning med 1, 10, 20
Silgard, suspension for injection – pre-filled syringe with 2 needles, pack of 1, 10, 20
Silgard, suspension til injektion
Silgard, suspension for injection.
Silgards effekt hos 16-26-årige mænd blev vurderet i et klinisk, placebo-kontrolleret, dobbeltblindet, randomiseret fase III-studie (Protokol 020) med i alt 4.055 mænd, der blev inkluderet og vaccineret uden forudgående screening for tilstedeværelse af HPV-infektion.
The efficacy of Silgard in 16- through 26-year-old men was assessed in 1 placebo-controlled, double- blind, randomized Phase III clinical study (Protocol 020) including a total of 4,055 men who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Silgards effekt hos kvinder fra 24 til 45 år blev vurderet i et klinisk, placebo-kontrolleret, dobbeltblindet, randomiseret fase III-studie (protokol 019, FUTURE III) med i alt 3.817 kvinder, som blev inkluderet og vaccineret uden forudgående screening for tilstedeværelsen af HPV-infektion.
The efficacy of Silgard in 24- through 45-year-old women was assessed in 1 placebo-controlled, double-blind, randomized Phase III clinical study (Protocol 019, FUTURE III) including a total of 3,817 women, who were enrolled and vaccinated without pre-screening for the presence of HPV infection.
Silgards virkning på frekvensen af definitive cervikale behandlingsprocedurer uanset udløsende HPV- typer blev evalueret hos 18.150 personer rekrutteret til protokollerne 007, 013 og 015.
The impact of Silgard on rates of Definitive Cervical Therapy Procedures regardless of causal HPV types was evaluated in 18,150 individuals enrolled in Protocol 007, Protocols 013 and 015.
Silica Magnesiumstearat
Silicon dioxide Magnesium stearate
Silica, colloid vandfri
Silica, colloidal anhydrous
Silica, kolloid Croscarmellosenatrium Hypromelloseacetatsuccinat Lactosemonohydrat Magnesiumstearat
Colloidal silicon dioxide Croscarmellose sodium Hypromellose acetate succinate Lactose monohydrate Magnesium stearate
Silica, kolloid Dibutylsebacat
Colloidal silicon dioxide Dibutyl sebacate
Silica, kolloid Magnesiumstearat
Colloidal silicon dioxide Magnesium stearate
Silica, kolloid vandfri
Colloidal anhydrous silica
Silica, kolloid vandfri
Film-coat:
Silica, kolloid vandfri
Silica colloidal anhydrous
Silica, kolloid vandfri
Silica colloidal, anhydrous
Silica, kolloid vandfri
Silica, anhydrous colloidal
Silica, kolloid vandfri
Silica, Colloidal Anhydrous Magnesium Stearate
Silica, kolloid vandfri
Tablet coating:
Silica, kolloid vandfri Croscarmellosenatrium Magnesiumstearat Povidon
Silica, colloidal anhydrous Croscarmellose sodium Magnesium stearate Povidone
Silica, kolloid vandfri Filmovertræk
Film-coating
Silica, kolloid vandfri Hypromellose Macrogol
Silica, colloidal anhydrous
Silica, kolloid vandfri Isopropylmyristat Laktose
Colloidal anhydrous silica Isopropyl myristate Lactose.
Silica, kolloid vandfri Isopropylmyristat Laktose
Silica Colloidal anhydrous Isopropyl myristate Lactose.
Silica, kolloid vandfri Kapslen
Silica, colloidal anhydrous Capsule shell
Silica, kolloid vandfri Magnesiumstearat
Coating: Hypromellose
Silica, kolloid vandfri Magnesiumstearat
Lactose monohydrate Croscarmellose sodium Sodium chloride Colloidal anhydrous silica Magnesium stearate
Silica, kolloid vandfri Magnesiumstearat
Silica colloidal anhydrous Magnesium stearate
Silica, kolloid vandfri Natriumhydroxid (E524) Natriumstearylfumarat Sorbitol (E420)
Silica, colloidal anhydrous Sodium hydroxide (E524) Sodium stearyl fumarate Sorbitol (E420)
Silica, kolloid vandfri Natriumstearylfumarat
Colloidal anhydrous silica Sodium stearyl fumarate
Silica, kolloid vandfri Polysorbat 80
Silica, colloidal anhydrous Polysorbate 80
Silica, kolloid vandfri Renset vand
Titanium dioxide (E171) Sodium laurilsulphate Silica, colloidal anhydrous Purified water
Silica, kolloid vandfri Siliciumdioxid, vandfri Natriumlaurilsulfat Prægelatiniseret stivelse Ravsyre
Silica, colloidal anhydrous Silicon dioxide anhydrous Sodium laurilsulfate Starch pregelatinised Succinic acid
Silica, kolloid vandfri.
Silica, colloidal anhydrous
Silica, kolloid vandfrit
Silica, colloidal anhydrous
Silica, kolloid, vandfri
Silica colloidal anhydrous
Silica, kolloid, vandfri
Silica, anhydrous colloidal
Silica, kolloid, vandfri Magnesiumstearat Triethylcitrat
Silica, colloidal anhydrous Magnesium stearate Triethyl citrate
Silica, kolloid, vandfri Vinsyre
Silica colloidal anhydrous Tartaric acid
Silica, vandfri kolloid Magnesium stearat
Silica, colloidal anhydrous Magnesium stearate
Silica-aktiveret koagulationstid (SCT) i op til 18 timer, og
Silica Clot Time (SCT) for up to 18 hours, and
Silica-aktiveret koagulationstid (SCT) Op til 18 timer
Silica clot time (SCT) Up to 18 hours
Silicagel- tørremidlet er i et separat brev eller en separat beholder og må ikke sluges.
The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
Silicificeret mikrokrystallinsk cellulose
Silicified microcrystalline cellulose Artificial powdered beef flavour Croscarmellose sodium
Silicificeret mikrokrystallinsk cellulose Pulver med kunstig kødsmag Croscarmellosenatrium Natriumlaurilsulfat
Silicified microcrystalline cellulose Artificial powdered beef flavour Croscarmellose sodium
Siliciumdioxid, kolloid Magnesiumstearat
Colloidal silicon dioxide Magnesium stearate
Silikondioxid Magnesiumstearat.
Silicon dioxide Magnesium stearate.
Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA Storbritannien
Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA United Kingdom
Silk Road Business Park, Macclesfield, SK10 2NA Storbritannien
Silk Road Business Park, Macclesfield, SK10 2NA United Kingdom
Sillica, kolloid vandfri Magnesiumstearat
Silica colloidal anhydrous Magnesium stearate
Silodosin er ikke blevet evalueret hos patienter under 18 år.
Silodosin has not been evaluated in patients less than 18 years of age.
Silodosin har et fordelingsvolumen på 0,81 l/kg og en plasmaproteinbinding på 96,6 %.
Silodosin has a volume of distribution of 0.81 l/kg and is 96.6 % bound to plasma proteins.
Silodosin Tamsulosin
Silodosin
Silodosinglukuronids proteinbinding er 91 %.
Protein binding of silodosin glucuronide is 91 %.
Silodyx 4 mg er gule, uigennemsigtige, hårde gelatinekapsler.
Silodyx 4 mg are yellow, opaque, hard gelatin capsules.
Silodyx 4 mg hårde kapsler silodosin
Silodyx 4 mg hard capsules silodosin
Silodyx 8 mg hårde kapsler silodosin
Silodyx 8 mg hard capsules silodosin
Silodyx 8 mg hårde kapsler Silodyx 4 mg hårde kapsler Silodosin
Silodyx 8 mg hard capsules Silodyx 4 mg hard capsules Silodosin
Silodyx bør ikke anvendes til patienter med svært nedsat nyrefunktion.
In patients with severe renal impairment administration of Silodyx is not recommended.
Silodyx findes i pakningsstørrelser med 5, 10, 20, 30, 50, 90 og 100 kapsler.
Silodyx is available in packs containing 5, 10, 20, 30, 50, 90, 100 capsules.
Silodyx kan forårsage komplikationer under en operation for grå stær (øjenoperation på grund af en uklar linse, se punkt “Advarsler og forsigtighedsregler”).
Silodyx may cause complications during a cataract surgery (eye surgery because of cloudiness of the lens, see section “Warnings and precautions”).
Silodyxs anvendelse
What Silodyx is used for
Siltuximab er udformet, så det bindes til det kemiske signalstof interleukin 6 (IL-6).
Siltuximab has been designed to attach to and block the activity of a protein in the body called interleukin 6 (IL-6).
siltuximab.
treatment with siltuximab.
Siltuximabs immunogenicitet blev evalueret ved hjælp af metoderne antigen-bridging enzym-immunoassay (EIA) og elektrokemiluminiscens- (ECL-) baseret immunoassay (ECLIA).
The immunogenicity of siltuximab has been evaluated using antigen-bridging enzyme immunoassay (EIA) and electrochemiluminescence (ECL)-based immunoassay (ECLIA) methods.
Siltuximabs sikkerhed og virkning er ikke klarlagt hos pædiatriske patienter.
The safety and efficacy of siltuximab have not been established in paediatric patients.
SIMBRINZA 10 mg/ml + 2 mg/ml øjendråber Brinzolamid/brimonidin-tartrat
SIMBRINZA 10 mg/ml + 2 mg/ml eye drops Brinzolamide/brimonidine tartrate
SIMBRINZA 10 mg/ml + 2 mg/ml øjendråber, suspension Brinzolamid/brimonidintartrat
SIMBRINZA 10 mg/ml + 2 mg/ml eye drops, suspension Brinzolamide/brimonidine tartrate
SIMBRINZA anbefales ikke til børn og unge (se pkt.
SIMBRINZA is not recommended in children or adolescents (see section 4.4).
Simbrinza anbefales ikke til børn og unge under 18 år.
SIMBRINZA is not recommended for children and adolescents under 18 years of age.
Simbrinza bruges til at sænke trykket i øjet hos voksne patienter (over 18 år), som har øjenlidelserne glaukom (grøn stær) eller forhøjet tryk i øjet, og hvor det høje tryk i øjet ikke kan bringes effektivt under kontrol med en medicin alene.
SIMBRINZA is used to lower pressure in the eyes in adult patients (aged more than 18 years) who have eye conditions known as glaucoma or ocular hypertension and whose high pressure in the eyes cannot be controlled effectively by one medicine alone.
SIMBRINZA bør ikke anvendes af ammende mødre.
SIMBRINZA should not be used by women nursing infants.
SIMBRINZA bør ikke anvendes under graviditeten eller til kvinder i den fertile alder, som ikke anvender sikker kontraception.
SIMBRINZA is not recommended during pregnancy and in women of child bearing potential not using contraception.
SIMBRINZA er beregnet til at virke lokalt indeni øjet.
SIMBRINZA is intended for local action within the eye.
SIMBRINZA er kontraindiceret hos patienter, der behandles med monoamin-oxidaseinhibitorer og patienter på antidepressiva, som påvirker den noadrenerge transmission (f.eks. tricykliske antidepressiva og mianserin) (se pkt.
SIMBRINZA is contraindicated in patients receiving monoamine oxidase inhibitors and patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin), (see section 4.3).
Simbrinza indeholder 2 aktive indholdsstoffer: brinzolamid og brimonidin-tartrat.
SIMBRINZA contains two active substances, brinzolamide and brimonidine tartrate.
SIMBRINZA indeholder 2 aktive indholdsstoffer: brinzolamid og brimonidintartrat.
SIMBRINZA contains two active substances: brinzolamide and brimonidine tartrate.